scholarly journals Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands

2017 ◽  
Vol 23 (3) ◽  
pp. 482-489 ◽  
Author(s):  
Johannes J. M. Kwakman ◽  
G. Vink ◽  
J. H. Vestjens ◽  
L. V. Beerepoot ◽  
J. W. de Groot ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
The Netherlands ◽  
Metastatic Colorectal Cancer ◽  
Real Life ◽  
Life Data ◽  
Real Life Data

scholarly journals Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data

2020 ◽  
Vol 148 (2) ◽  
pp. 296-306
Author(s):  
Patricia A. H. Hamers ◽  
Marloes A. G. Elferink ◽  
Rebecca K. Stellato ◽  
Cornelis J. A. Punt ◽  
Anne M. May ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Survival Time ◽  
Cancer Patients ◽  
Real Life ◽  
Life Data ◽  
Real Life Data ◽  
Colorectal Cancer Patients ◽  
Multiple Scenarios

Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival based on real-life data.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 32-32
Author(s):  
Patricia Hamers ◽  
Marloes A.G. Elferink ◽  
Rebecca K. Stellato ◽  
Cornelis J. A. Punt ◽  
Anne Maria May ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Systemic Therapy ◽  
Total Population ◽  
Real Life ◽  
Case Scenario ◽  
Worst Case ◽  
Life Data ◽  
Real Life Data ◽  
Multiple Scenarios

32 Background: Reported median overall survival (mOS) in trials of metastatic colorectal cancer (mCRC) patients receiving systemic therapy has increased to over 30 months. When informing patients, many clinicians quote the mOS reported in these trials. It is uncertain whether trial results translate to real-life populations. Moreover, patients prefer presentation of multiple survival scenarios over presentation of just mOS. Therefore, we quantified multiple scenarios for survival time of real-life mCRC patients. Methods: Nationwide population-based data of all stage IV CRC patients diagnosed between 2008 and 2016 were obtained from the Netherlands Cancer Registry. We calculated percentiles (scenarios) of OS per year of diagnosis for the total population, and for treatment subgroups: 10th (best-case), 25th (upper-typical), 50th (median), 75th (lower-typical), and 90th (worst-case). Results: The total study population comprised 27,275 patients. Twenty-five percent these patients did not receive any antitumor treatment. From 2008-2016, mOS of the total population remained unchanged at approximately 12 months. OS improved only for the upper-typical and best-case patients; by 4.2 to 29.1 months (p<0.001), and by 6.0 months to 62.0 months (p<0.001), respectively. No clinically relevant change was seen among patients who received systemic therapy, with mOS close to 15 months and best-case scenario approximately 40 months. mOS and worst-case scenario for survival were highest in patients who underwent both metastasectomy and systemic therapy: around 48 and 15 months, respectively. A clinically relevant improvement in survival over time was observed only in patients who initially received metastasectomy without systemic treatment. Conclusions: In contrast to the wide belief that mOS of mCRC patients receiving systemic therapy has improved substantially, improvement could not be demonstrated in our real-life population. Clinicians should consider quoting multiple scenarios for survival based on real-life data, instead of point estimates from clinical trials, when informing patients about their life expectancy.

scholarly journals A Novel Computational Tool for Mining Real-Life Data: Application in the Metastatic Colorectal Cancer Care Setting

PLoS ONE ◽  
2016 ◽  
Vol 11 (5) ◽  
pp. e0154689
Author(s):  
Nava Siegelmann-Danieli ◽  
Ariel Farkash ◽  
Itzhak Katzir ◽  
Janet Vesterman Landes ◽  
Hadas Rotem Rabinovich ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Care ◽  
Care Setting ◽  
Real Life ◽  
Computational Tool ◽  
Life Data ◽  
Data Application ◽  
Real Life Data

Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in the Netherlands: A population-based study.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 6612-6612
Author(s):  
Lotte Keikes ◽  
Miriam Koopman ◽  
Martijn M. Stuiver ◽  
Valery Lemmens ◽  
Martijn G.H. van Oijen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
The Netherlands ◽  
Metastatic Colorectal Cancer ◽  
Systemic Therapy ◽  
Systemic Treatment ◽  
Real Life ◽  
Population Based ◽  
Practice Variation ◽  
Current Guideline ◽  
Hospital Variation

6612 Background: Population-based data on the implementation of guidelines for cancer patients in daily practice are scarce. Therefore, we evaluated practice variation patterns and associated variables in the systemic treatment of metastatic colorectal cancer (mCRC) between 2008 and 2015 in the Netherlands. Methods: We selected a random sample of adult mCRC patients diagnosed from 2008 to 2015 from the National Cancer Registry in 20 Dutch hospitals. We examined the influence of patient, demographic and tumor characteristics on the odds of being treated with systemic therapy according to the current guideline and assessed its association with survival. Results: Our study population consisted of 2222 mCRC patients of whom 1307 patients received systemic therapy for mCRC. Practice variation was most obvious in the use of bevacizumab and anti-EGFR therapy in patients with (K)RAS wild-type tumors. Administration rates did not differ between hospital types but fluctuated between individual hospitals for bevacizumab (8-92%; p<0·0001) and anti-EGFR therapy (10-75%; p=0·05). Bevacizumab administration was inversely correlated to higher age (OR:0·2; 95% CI: 0·1-0·3) comorbidity (OR:0·6; 95% CI: 0·5-0·8) and the presence of metachronous metastases (OR:0·5; 95% CI: 0·3-0·7), but patient characteristics did not differ between hospitals with low or high bevacizumab administration rates. Exposure to bevacizumab (HR:0·8; 95% CI: 0·7-0·9) and anti-EGFR therapy (HR:0·6; 95% CI: 0·5-0·8) was associated with prolonged survival. Conclusions: We identified significant inter-hospital variation in targeted therapy administration for mCRC patients, which may affect outcome. Age and comorbidity were inversely correlated with non-administration of bevacizumab, but did not explain inter-hospital practice variation. Our data strongly indicate that practice variation is based on individual strategy of hospitals rather than guideline recommendations or patient-driven decisions. Individual hospital strategies are an additional factor that may explain the observed differences between real-life data and results obtained from clinical trials.

The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study

2020 ◽  
Author(s):  
Ismail Beypinar ◽  
Hacer Demir ◽  
Abdullah Sakin ◽  
Burcu Yapar Taskoylu ◽  
Teoman Sakalar ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Braf Mutation ◽  
Real Life ◽  
The Real ◽  
Life Data ◽  
Real Life Data

Neuropsychology in the Real World

2014 ◽  
Vol 25 (4) ◽  
pp. 233-238 ◽  
Author(s):  
Martin Peper ◽  
Simone N. Loeffler
Keyword(s):  
Neuropsychological Assessment ◽  
Real World ◽  
Ecological Validity ◽  
Real Life ◽  
Emotional States ◽  
Context Sensitive ◽  
Traditional Assessment ◽  
Life Data ◽  
Real Life Data ◽  
Assessment And Treatment

Current ambulatory technologies are highly relevant for neuropsychological assessment and treatment as they provide a gateway to real life data. Ambulatory assessment of cognitive complaints, skills and emotional states in natural contexts provides information that has a greater ecological validity than traditional assessment approaches. This issue presents an overview of current technological and methodological innovations, opportunities, problems and limitations of these methods designed for the context-sensitive measurement of cognitive, emotional and behavioral function. The usefulness of selected ambulatory approaches is demonstrated and their relevance for an ecologically valid neuropsychology is highlighted.

Sign in / Sign up

Export Citation Format

Share Document